This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China

This study has been completed.
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company ) Identifier:
First received: January 14, 2011
Last updated: March 28, 2013
Last verified: March 2013

The aim of the study is to collect post marketing safety data on IMOVAX Polio vaccine in China.


To describe serious adverse events 30 days after each dose of IMOVAX Polio™ administered at 2, 3, and 4 months of age among infants living in the study cities of China.

Condition Intervention Phase
Polio Poliomyelitis Biological: IMOVAX Polio™: Inactivated Poliomyelitis Vaccine Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study

Resource links provided by NLM:

Further study details as provided by Sanofi ( Sanofi Pasteur, a Sanofi Company ):

Primary Outcome Measures:
  • Number of participants reporting serious adverse events and relationship to Imovax Polio vaccination. [ Time Frame: Up to 30 days after each vaccination ]
    A serious adverse event is defined as any untoward medical occurrence that at any dose (including overdose) results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect, or is an important medical event.

Enrollment: 5007
Study Start Date: December 2010
Study Completion Date: June 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Study Group
Participants receiving their first dose of polio vaccine
Biological: IMOVAX Polio™: Inactivated Poliomyelitis Vaccine
0.5 mL, Intramuscular
Other Name: IMOVAX Polio™

Detailed Description:
Each study participant will receive an IMOVAX Polio™ injections at 2, 3 and 4 months of age (total of 3 doses) and will be followed up for 30 days after each vaccination.

Ages Eligible for Study:   60 Days to 89 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject is 2 months of age or older (60-89days) when receiving the first dose of polio vaccine.
  • Subject's parent /legal representative showed willingness to complete the 3 primary doses fully using IMOVAX Polio according to the schedule. one injection at 2, 3, 4 months old respectively;
  • Informed consent form obtained by the subject's parent/legal representative.
  • Subject plan to live in the selected study sites for at least three months after inclusion.

Exclusion Criteria:

  • Subject with a history of serious illness (i.e., hypersensitivity, seizure, convulsion, encephalopathy diseases, etc.)
  • Acute medical illness with or without fever within the last 72 hours.
  • Vaccination planned in the 4 weeks following any trial vaccination (except Diphtheria, Tetanus, Pertussis (DTP), Hib vaccine or Pneumo vaccine)
  • Participation in another clinical trial at the same time.
  • Contraindications to vaccination according to IMOVAX Polio™ leaflet.
  • Subject plan to leave the study sites for at least three months after inclusion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01278433

China, Beijing
Beijing, Beijing, China, 100050
Chang Sha, China
Cheng Du, China
Chong Qing, China
Hang Zhou, China
Ji Nan, China
Kun Ming, China
Nan Jing, China
Qing Dao, China
Shen Yang, China
Shen Zhen, China
Tian Jin, China
Wu Han, China
Xi An, China
Zheng Zho, China
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
Study Director: Medical Director Sanofi Pasteur China
  More Information

Additional Information:
Responsible Party: Sanofi Pasteur, a Sanofi Company Identifier: NCT01278433     History of Changes
Other Study ID Numbers: IPV34
UTN: U1111 1115 6566 ( Other Identifier: WHO )
Study First Received: January 14, 2011
Last Updated: March 28, 2013

Keywords provided by Sanofi ( Sanofi Pasteur, a Sanofi Company ):

Additional relevant MeSH terms:
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases
Spinal Cord Diseases
Neuromuscular Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017